Hematological malignancies encompass a diverse range of diseases, such as leukemia, lymphoma, and multiple myeloma, among others. Within the multidisciplinary treatment approach, radiation therapy ...

The FDA has approved the first all-oral, fixed-duration first-line regimen for treatment of chronic lymphocytic leukemia and ...

Annual meeting moves to the New York Marriott Marquis on October 13-16, marking a new chapter and providing a refreshed ...

What's new in proton therapy? Read the latest news and views from Fred Hutch's proton therapy facility’s patients and providers in The Beam, published monthly.

Recent regulatory actions from the FDA, including new drug application (NDA) acceptances and labeling updates, introduce new clinical considerations for oncology nurses and advanced practice providers ...

The FDA has started a priority review of iberdomide as an add-on to Johnson & Johnson and Genmab's anti-CD38 antibody Darzalex (daratumumab) and dexamethasone, a standard regimen for relapsed or ...

Accord Healthcare, Inc., a leading U.S. pharmaceutical company, today announced the launch of Lenalidomide Capsules in the United States, reinforcing the company's commitment to expanding access to ...

According to MarketsandMarketstm, the CAR T-Cell Therapy Market is estimated to reach USD 13.78 billion by 2031 from USD 7.24 billion in 2026, at a CAGR of 13.7%. Browse 300 market data Tables and 30 ...

According to MarketsandMarkets, the CAR T-Cell Therapy Market is estimated to reach USD 13.78 billion by 2031 from USD 7.24 billion in 2026 ...

A recent review concluded that artificial intelligence (AI) is rapidly transforming the diagnosis and treatment of haematological malignancies by enhancing diagnostic accuracy and ...

The growth of the BCL-2 inhibitors market is expected to be driven primarily by rising incidence, increased awareness and access to treatment, and the launch of emerging drugs such as Lisaftoclax ...